Trial Profile
Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS3)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 23 Jan 2013 New trial record